Pharmacokinetics of Tedizolid in Subjects with Renal or Hepatic Impairment

Two open-label, single-dose, parallel-group studies were conducted to characterize the pharmacokinetics of the novel antibacterial tedizolid and the safety of tedizolid phosphate, its prodrug, in renally or hepatically impaired subjects. Tedizolid pharmacokinetics in subjects with severe renal impai...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Antimicrob Agents Chemother
Main Authors: Flanagan, S., Minassian, S. L., Morris, D., Ponnuraj, R., Marbury, T. C., Alcorn, H. W., Fang, E., Prokocimer, P.
Format: Artigo
Jezik:Inglês
Izdano: American Society for Microbiology 2014
Teme:
Pharmacology
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4249404/
https://ncbi.nlm.nih.gov/pubmed/25136024
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.03431-14
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki